Question 1

Am I eligible for this trial based on my recent surgery and cancer history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my situation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

Question 4

What kind of monitoring or tests will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to visit the clinic for treatment and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence clinical trial (NCT06682728). Contact the study team or your healthcare provider for specific answers.

What this study is about